RT @DrPetryna: @RheumNow #acr19 abs2876 GODACT ph3 trial: glimumab+MTX improves clinical& MRI dactylitis scores better than MTX mono. mean…

Social Author Image
https://pbs.twimg.com/profile_images/1010360126954491904/BUlKU6N_.jpg
Tweet Author
DrPetryna
Social Author Name
Olga Petryna
Tweet Content
@RheumNow #acr19 abs2876 GODACT ph3 trial: glimumab+MTX improves clinical& MRI dactylitis scores better than MTX mono. mean MTX dose in the golimumab+ MTX group 16.3mg/wk & 19.2mg/wk in the MTX mono group . Also better DAS28,DAPSA,PASDAS& tNAPSI at wk 24 in golimumab group
Show on Archive Page
On
Display in Search Results
On

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×